FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list

An FDA advisory committee voted 8-6 to add BPC-157, a peptide currently available only on grey and black markets, to the compounding drug list — a non-binding decision that would allow legal prescription access in the US despite minimal human clinical trial data on safety or efficacy.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.